Am J Med. 2022 Jan 29:S0002-9343(22)00026-2. doi: 10.1016/j.amjmed.2022.01.006. Online ahead of print.
ABSTRACT
Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues, frequently at a distance from the site of synthesis. The two most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy. Diagnosis can be challenging, and abundant suspicion is required to identify patients. As neurological manifestations of amyloidosis may precede involvement of other organs by several years, recognizing amyloid neuropathy and myopathy are crucial, especially in this new and exciting era of effective therapies for AL and ATTR neuropathy. This review will focus on the neuromuscular manifestations of AL and ATTR amyloidosis, diagnostic approaches and recent advances in the treatment of amyloid neuropathy.
PMID:35104443 | DOI:10.1016/j.amjmed.2022.01.006